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Practice
the clinical problem
Strategies to prevent vascular events (stroke, myocardial 
infarction, or vascular death) after an ischaemic stroke 
or transient ischaemic attack (TIA) include using aspi-
rin, which is the most widely tested single antiplatelet 
drug for this purpose.1 2 Adding dipyridamole further 
reduces the risk in patients who have had an ischaemic 
stroke or transient ischaemic attack. 
the evidence for change 
Sources of evidence are in the box on bmj.com.1-3 
The second European stroke prevention study 
(ESPS-2) found, in 3299 patients with a prior ischae-
mic stroke or transient ischaemic attack, that dipyri-
damole plus aspirin significantly reduced the relative 
risk of vascular events by about a fifth compared with 
aspirin alone.1 4-6 However, pooled data from previ-
ous randomised trials in several thousand patients at 
high risk of vascular events (about 1800 of whom had 
a prior ischaemic stroke or transient ischaemic attack) 
did not find that adding dipyridamole reduced vas-
cular events.1 5 6 The contrasting ESPS-2 results were 
attributed to chance; the very low daily dose (50 mg) 
of aspirin used compared with previous trials; or the 
particular daily dose and preparation (400 mg modified 
release v ≤300 mg standard preparation) of dipyrida-
mole used.1 7
The recently published European/Australasian stroke 
prevention in reversible ischaemia trial (ESPRIT) 
compared aspirin plus dipyridamole versus aspirin 
alone in 2739 patients with a prior ischaemic stroke 
or transient ischaemic attack.5 The resulting relative 
reduction in vascular events was the same as in ESPS-2, 
and a meta-analysis of all randomised trials comparing 
the combination with aspirin alone in patients with a 
prior ischaemic stroke or transient ischaemic attack 
largely reflected the results of the ESPS-2 and ESPRIT 
trials.5
Assuming a baseline risk of vascular events of 5% a 
year, the annual risk in the aspirin only arm of ESPRIT 
(reflecting well the risk in patients already receiving cur-
rent secondary preventive treatments), the addition of 
dipyridamole would prevent about 10 vascular events 
per 1000 patients treated per year).5
Neither large trial found an excess of major bleed-
ing in patients allocated the combination compared 
with aspirin alone. However, both reported a higher 
rate of premature cessation of treatment in the com-
bination than in the aspirin arm, mainly as a result 
of adverse effects (particularly dipyridamole induced 
headache, which may occur in up to a third of people 
receiving dipyridamole but usually settles in one to two 
weeks and might be reduced by dipyridamole dose 
titration).4 5 8
Barriers to change
Doctors or patients may perceive that the small abso-
lute benefit is not worth while, and adherence may 
be limited by adverse effects and the difficulties for a 
predominantly elderly population to take additional 
medication. As rapid intravenous injection of dipyri-
damole reduces blood pressure when it is used as a 
coronary vasodilator in stress echocardiography and 
thallium imaging, anxieties have been expressed about 
dipyridamole in patients with ischaemic heart disease.7 
However, in ESPRIT, long term oral dipyridamole did 
not affect blood pressure, and the benefits of adding 
dipyridamole to aspirin were similar in those with and 
without ischaemic heart disease.5 9 Cost may be a bar-
rier, as in the United Kingdom modified release dipy-
ridamole 200 mg twice daily costs £102 (€150; $200) a 
patient per year, compared with £5 a patient per year 
for aspirin 75 mg daily.10 
how should we change our practice?
Ensure first that
•  The diagnosis of ischaemic stroke or transient 
ischaemic attack is correct (which generally 
requires prompt specialist assessment and 
appropriate investigations)
•  Existing secondary preventive strategies (such 
as lifestyle advice, aspirin, and reduction in 
cholesterol and blood pressure) have been or are 
being considered and used where appropriate
•  No reason (such as atrial fibrillation) exists to 
consider anticoagulants instead of antiplatelet 
treatment
•  The patient is already taking and tolerating 
aspirin, the most appropriate dose being  
75-150 mg daily as higher doses produce more 
gastrointestinal side effects and lower doses may 
be less effective.1 7
Then discuss with the patient (or proxy) the likely 
absolute benefit of adding modified release dipyrida-
mole 200 mg twice daily (that is, on average about 
a 1 in 100 chance per year of benefiting) versus the 
potential for adverse effects and the inconvenience of 
extra pills. Start dipyridamole if the patient wishes; it 
can be continued long term if tolerated and if no con-
traindications develop and funding allows.
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keY Points  
•	In	patients	with	a	prior	
ischaemic	stroke	or	
transient	ischaemic	attack,	
adding	the	antiplatelet	
drug	dipyridamole	
(modified	release	
formulation,	200	mg	twice	
daily)	to	aspirin	reduces	
the	relative	risk	of	vascular	
events	(stroke,	myocardial	
infarction,	or	vascular	
death)	by	a	fifth
•	In	patients	already	
receiving	current	
secondary	preventive	
treatment,	the	average	
annual	risk	of	a	vascular	
event	is	no	more	than	
5%;	adding	dipyridamole	
prevents	one	further	
vascular	event	for	every	
100	patients	treated	each	
year
•	Headache	may	occur	
in	up	to	a	third	of	people	
taking	dipyridamole	but	
usually	settles	in	one	to	
two	weeks
